Search by property

This page provides a simple browsing interface for finding entities described by a property and a named value. Other available search interfaces include the page property search, and the ask query builder.

List of results

• Pace et al. (2003): Neuroprotective Effect of Vitamin E Supplementation in Patient Treated With Cisplatin Chemotherapy  + (T0: prior to chemotherapy T1: after 3. chemotherapy-cycle T2: 1 month after chemotherapy)
• Lyckholm et al. (2012): A randomized, placebo controlled trial of oral zinc for chemotherapy-related taste and smell disorders  + (T0: prior to intervention T1-T3: at 1, 2, and 3 months after initiating zinc versus placebo)
• Ripamonti et al. (1998): A randomized, controlled clinical trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation  + (T0: prior to radiotherapy, weekly intervals during radiotherapy Follow-Up: 1 month after radiotherapy)
• Cavallini et al. (2005): Acetyl-L-carnitine plus propionyl-L-carnitine improve efficacy of sildenafil in treatment of erectile dysfunction after bilateral nerve-sparing radical retropubic prostatectomy  + (T0: prior to therapy T1: 4 month of therapy)
• Hejazi et al. (2013): A pilot clinical trial of radioprotective effects of curcumin supplementation in patients with prostate cancer  + (T0: week -1 radiotherapy T1: 3 months after radiotherapy (20 weeks after T0))
• Hejazi et al. (2016): Effect of Curcumin Supplementation During Radiotherapy on Oxidative Status of Patients with Prostate Cancer: A Double Blinded, Randomized, Placebo-Controlled Study  + (T0: week -1 radiotherapy T1: 3 months after radiotherapy (20 weeks after T0))
• Scher et al. (2011): Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer  + (T0: within 14 days of random assignment 72 hours preceding each day 2 Follow-Up: after 48 weeks (only for survival))
• Braik et al. (2014): Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy  + (T1-T4: week 3 of each chemotherapy cycle)
• Panahi et al. (2012): Effect of Ginger on Acute and Delayed Chemotherapy-Induced Nausea and Vomiting: A Pilot, Randomized, Open-Label Clinical Trial  + (T1: 0-6h after Chemotherapy T2: 6-24h after Chemotherapy T3: 2nd day T4: 3rd day T5: 4th day)
• Montazeri et al. (2013): Effect of Herbal Therapy to Intensity Chemotherapy-Induced Nausea and Vomiting in Cancer Patients  + (T1: 1h after last capsule T2: after 2h T3: after 3h T4: after 4h T5: 24h after chemotherapy)
• Marx et al. (2017): The Effect of a Standardized Ginger Extract on Chemotherapy-Induced Nausea-Related Quality of Life in Patients Undergoing Moderately or Highly Emetogenic Chemotherapy: A Double Blind, Randomized, Placebo Controlled Trial  + (T1: 1st cycle of chemotherapy (assessment from 3 days before to 4 days after) T2: 2nd cycle of chemotherapy (assessment from 3 days before to 4 days after) T3: 3rd cycle of chemotherapy (assessment from 3 days before to 4 days after))
• Bossi et al. (2017): A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin  + (T1: Cycle 1 (day 2 to day 21 or 28) T2: Cycle 2 (day 23 or 30 to day 42 or 56))

• Fahimi et al. (2011): Evaluating the Effect of Zingiber Officinalis on Nausea and Vomiting in Patients Receiving Cisplatin Based Regimens  + (T1: Day 1 T2: Day 2 T3: Day 3)

• Arslan et al. (2015): Oral Intake of Ginger for Chemotherapy-Induced Nausea and Vomiting Among Women With Breast Cancer  + (T1: Day 1 (i.e. day of the chemotherapy infusion) T2: Day 2 (i.e. day after chemotherapy infusion) T3: Day 3 T4: Day 4 T5: Day 5)
• Konmun et al. (2017): A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy  + (T1: Day 1 (i.e. first day of chemotherapy administration) T2: Day 2 T3: Day 3 T4: Day 4 T5: Day 5 T6: Day 22 T7: Day 43 T8: Day 64)
• Mondal et al. (2014): Comparative study among glutamine, acetyl-L-carnitine, vitamin-E and methylcobalamine for treatment of paclitaxel-induced peripheral neuropathy  + (T1: after 3 chemotherapy cycles T2: after 6 chemotherapy cycles T3: 6 months post-chemotherapy)
• Portenoy et al. (2012): Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial  + (T1: baseline (3 days) T2: day 21 T3: day 35 (end of intervention) T4: 14 days after treatment)
• Paur et al. (2017): Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA  + (T1: before intervention T2: after intervention (directly before radiotherapy/surgery))
• Puri et al. (2010): Lycopene in treatment of high-grade gliomas: A pilot study  + (T1: pre-radiotherapy T2: post-radiotherapy T3: 6 months after radiotherapy)
• Mahmoodnia et al. (2017): Ameliorative effect of lycopene effect on cisplatin-induced nephropathy in patients  + (T1: start of the study T2: day 7 of chemotherapy T3: day 21 of chemotherapy)
• Minchom et al. (2014): An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of (...)  + (Unclear, dependent on specific outcome)
• Halyard et al. (2007): Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4)  + (Weekly during radiotherapy; At 1, 2, 3, and 6 months after radiotherapy completion)
• Watanabe et al. (2010): Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer  + (Weekly observartions)
• Mazdak et al. (2012): Vitamin E reduces superficial bladder cancer recurrence: A randomized controlled Trial  + (Year 1-2 examined every 3 months, then every 6 months)